Key facts
- This page summarizes David S. Grayzel's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2024, 18:00.
David S. Grayzel - 02 Jan 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Director
- Issuer ticker
- JBIO
- Reported as of
- 02 Jan 2024
- Net transaction value
- +$42,979
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2024, 18:00:18 UTC
- Prior SEC filing
- 08 Sep 2023
- Next SEC filing
- 27 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ommer Chohan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David S. Grayzel filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 04 Jan 2024.
Change
- Previous filing in this sequence was filed on 08 Sep 2023.
- Current net transaction value: +$42,979.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $42,979
- Shares
- +3,186
- Change %
- Price
- $13.49
- Shares after
- 3,186
- Date
- 02 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,186
- Exercise price
- $21.81
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four substantially equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.
Footnote F2
This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.